Lavracin

General Information


DCTPep ID  DCTPep00771

Peptide Name   Lavracin

Sequence  WDPYFAGVKKLTKAILAVRA

Sequence Length  20

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

ACP Tumor active peptide



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
MEC-7 Invasive breast carcinoma of no special type EC50=(50-100)µM MTT assay 72h 1
MEC-7 Invasive breast carcinoma of no special type Not active up to 100 µM MTT assay 72h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HDME: Not active up to 100 µM

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep00771

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C108H171N27O25

Absent amino acids  CEHMNQS

Theoretical pI  10.00

Acidic residues  1

Basic residues  4

Polar residues  3

Molecular weight (Average)  2247.71

Molecular weight (Monoisotopic)  2246.29

Common amino acids  A

Net charge  3

Instability index (II)  13.44

Aliphatic index  107.50

Grand average of hydropathicity (GRAVY)  0.295

Half Life 
  2.8 hours (mammalian reticulocytes, in vitro).
  3 min (yeast, in vivo).
  2 min (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 6990
  Abs 0.1% (=1 g/l) 3.110

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 28799716

Title  Rational Design of Membrane-Pore-Forming Peptides.

Doi 10.1002/smll.201701316

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DCTPep is developed by Dr.Zheng's team.